I re-visited the slides from recent presentations and in the Market Opportunity slides, they include a footnote that reads "2021 market entry in EU; 2023 market entry in US, Japan to follow EU registration path." So even if they file the NDA/MMA in 2019, it appears that they are not expecting "market entry" until much later. So money from apabetalone sales sounds like it is still a ways off. So re-visiting that Zacks statement "The CAD$10 million capital raise should be sufficient to provide the flexibility to negotiate a larger licensing or first right of refusal deal that will support clinical trials and operations until a new drug application can be submitted to the FDA, which we anticipate occurring in 2019."........I'm not clear on why supporting clinical trials and operations only up until NDA submission is such a critical junction.

BDAZ